Endocrinology / diabetes clinical trials recruiting in New York

50 recruiting endocrinology / diabetes trials match in New York. Showing 20.

• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Recruiting

  Phase 3 · AstraZeneca · Bay Shore, New York

• Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruiting

  Phase 2 · National Cancer Institute (NCI) · Rochester, New York

• Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomesRecruiting

  Phase 4 · VA Office of Research and Development · New York, New York

• Maternal Smoking Cessation and Pediatric Obesity PreventionRecruiting

  N/A · State University of New York at Buffalo · Buffalo, New York

• A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionRecruiting

  Phase 2 · Incyte Corporation · New York, New York

• NYSCF Scientific Discovery BiobankRecruiting

  N/A · New York Stem Cell Foundation Research Institute · New York, New York

• A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecruiting

  Phase 1 · Seagen, a wholly owned subsidiary of Pfizer · Babylon, New York

• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruiting

  Phase 2 · National Cancer Institute (NCI) · Buffalo, New York

• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsRecruiting

  Phase 1 / Phase 2 · Day One Biopharmaceuticals, Inc. · New York, New York

• FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast CancerRecruiting

  Phase 1 · Regor Pharmaceuticals Inc. · Port Jefferson Station, New York

• AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightRecruiting

  Phase 3 · Novo Nordisk A/S · New York, New York

• Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialRecruiting

  Phase 2 · National Cancer Institute (NCI) · Buffalo, New York

• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityRecruiting

  Phase 3 · Amgen · Binghamton, New York

• A Study of Lower Radiotherapy Dose to Treat Children With CNS GerminomaRecruiting

  Phase 2 · Children's Oncology Group · Albany, New York

• A Study of LY4170156 in Participants With Selected Advanced Solid TumorsRecruiting

  Phase 1 · Eli Lilly and Company · Mineola, New York

• PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesRecruiting

  Phase 4 · Brigham and Women's Hospital · New York, New York

• A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionRecruiting

  Phase 2 · AbbVie · Los Angeles, California

• Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic FistulaRecruiting

  Phase 3 · SWOG Cancer Research Network · La Jolla, California

• Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityRecruiting

  Phase 3 · Pfizer · Scottsdale, Arizona

• Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple MyelomaRecruiting

  Phase 1 · Nammi Therapeutics Inc · New York, New York

Source: ClinicalTrials.gov. Recruitment status changes often — confirm on each study page.